Puma Biotechnology | PBYI - Trade Creditors


Puma Biotechnology reported $6.39M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Agios Pharmaceuticals USD 13.75M 4.61M Mar/2026
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
Amgen USD 19.52B 1.37B Mar/2026
Biogen USD 358.5M 73.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Daiichi Sankyo JPY 568.5B 16.84B Dec/2025
Esperion Therapeutics USD 68.41M 3.34M Mar/2026
Exelixis USD 24.15M 5.47M Mar/2026
Gilead Sciences USD 645M 70M Mar/2026
Glaxosmithkline GBP 20.72B 346.14M Dec/2025
Incyte USD 228.62M 1.41B Mar/2026
MacroGenics USD 4.29M 500K Mar/2026
Moderna USD 161M 156M Mar/2026
Novartis USD 4.32B 134M Mar/2026
Pfizer USD 4.51B 734M Mar/2026
PTC Therapeutics USD 25.48M 20M Mar/2026
Puma Biotechnology USD 6.39M 962K Sep/2025
Regeneron Pharmaceuticals USD 1.03B 4.81B Mar/2026
Roche Holding CHF 5.78B 1.27B Dec/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
Takeda JPY 491.34B 23.75B Mar/2026
TG Therapeutics USD 148.84M 41.34M Mar/2026
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024
Vertex Pharmaceuticals USD 3.47B 40.6M Mar/2026